The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-08-01 Epub Date: 2024-05-29 DOI:10.1097/MEG.0000000000002796
Sinéad M Smith, Breida Boyle, Martin Buckley, Conor Costigan, Maeve Doyle, Richard Farrell, M Syafiq Ismail, David Kevans, Sean Nugent, Anthony O'Connor, Colm O'Morain, Vikrant Parihar, Cristín Ryan, Deirdre McNamara
{"title":"The second Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of Helicobacter pylori infection in adult patients in Ireland.","authors":"Sinéad M Smith, Breida Boyle, Martin Buckley, Conor Costigan, Maeve Doyle, Richard Farrell, M Syafiq Ismail, David Kevans, Sean Nugent, Anthony O'Connor, Colm O'Morain, Vikrant Parihar, Cristín Ryan, Deirdre McNamara","doi":"10.1097/MEG.0000000000002796","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There has been an increase in resistance to many of the antimicrobials used to treat Helicobacter pylori ( H. pylori ) nationally and internationally. Primary clarithromycin resistance and dual clarithromycin and metronidazole resistance are high in Ireland. These trends call for an evaluation of best-practice management strategies.</p><p><strong>Objective: </strong>The objective of this study was to revise the recommendations for the management of H. pylori infection in adult patients in the Irish healthcare setting.</p><p><strong>Methods: </strong>The Irish H. pylori working group (IHPWG) was established in 2016 and reconvened in 2023 to evaluate the most up-to-date literature on H. pylori diagnosis, eradication rates and antimicrobial resistance. The 'GRADE' approach was then used to rate the quality of available evidence and grade the resulting recommendations.</p><p><strong>Results: </strong>The Irish H. pylori working group agreed on 14 consensus statements. Key recommendations include (1) routine antimicrobial susceptibility testing to guide therapy is no longer recommended other than for clarithromycin susceptibility testing for first-line treatment (statements 6 and 9), (2) clarithromycin triple therapy should only be prescribed as first-line therapy in cases where clarithromycin susceptibility has been confirmed (statement 9), (3) bismuth quadruple therapy (proton pump inhibitor, bismuth, metronidazole, tetracycline) is the recommended first-line therapy if clarithromycin resistance is unknown or confirmed (statement 10), (4) bismuth quadruple therapy with a proton pump inhibitor, levofloxacin and amoxicillin is the recommended second-line treatment (statement 11) and (5) rifabutin amoxicillin triple therapy is the recommend rescue therapy (statement 12).</p><p><strong>Conclusion: </strong>These recommendations are intended to provide the most relevant current best-practice guidelines for the management of H. pylori infection in adults in Ireland.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11198963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000002796","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There has been an increase in resistance to many of the antimicrobials used to treat Helicobacter pylori ( H. pylori ) nationally and internationally. Primary clarithromycin resistance and dual clarithromycin and metronidazole resistance are high in Ireland. These trends call for an evaluation of best-practice management strategies.

Objective: The objective of this study was to revise the recommendations for the management of H. pylori infection in adult patients in the Irish healthcare setting.

Methods: The Irish H. pylori working group (IHPWG) was established in 2016 and reconvened in 2023 to evaluate the most up-to-date literature on H. pylori diagnosis, eradication rates and antimicrobial resistance. The 'GRADE' approach was then used to rate the quality of available evidence and grade the resulting recommendations.

Results: The Irish H. pylori working group agreed on 14 consensus statements. Key recommendations include (1) routine antimicrobial susceptibility testing to guide therapy is no longer recommended other than for clarithromycin susceptibility testing for first-line treatment (statements 6 and 9), (2) clarithromycin triple therapy should only be prescribed as first-line therapy in cases where clarithromycin susceptibility has been confirmed (statement 9), (3) bismuth quadruple therapy (proton pump inhibitor, bismuth, metronidazole, tetracycline) is the recommended first-line therapy if clarithromycin resistance is unknown or confirmed (statement 10), (4) bismuth quadruple therapy with a proton pump inhibitor, levofloxacin and amoxicillin is the recommended second-line treatment (statement 11) and (5) rifabutin amoxicillin triple therapy is the recommend rescue therapy (statement 12).

Conclusion: These recommendations are intended to provide the most relevant current best-practice guidelines for the management of H. pylori infection in adults in Ireland.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
爱尔兰幽门螺杆菌工作组关于诊断和治疗爱尔兰成年患者幽门螺杆菌感染的第二次共识。
背景:在国内和国际上,用于治疗幽门螺旋杆菌(H. pylori)的许多抗菌药物的耐药性都在增加。在爱尔兰,原发性克拉霉素耐药性以及克拉霉素和甲硝唑双重耐药性很高。这些趋势要求对最佳管理策略进行评估:本研究旨在修订爱尔兰医疗机构中成年患者幽门螺杆菌感染的管理建议:爱尔兰幽门螺杆菌工作组(IHPWG)成立于 2016 年,并于 2023 年再次召开会议,评估有关幽门螺杆菌诊断、根除率和抗菌药耐药性的最新文献。然后采用 "GRADE "方法对现有证据的质量进行评级,并对由此产生的建议进行分级:爱尔兰幽门螺杆菌工作组达成了 14 项共识声明。主要建议包括:(1) 除一线治疗中的克拉霉素药敏试验外,不再建议使用常规抗菌药物药敏试验指导治疗(声明 6 和 9);(2) 克拉霉素三联疗法仅应在克拉霉素药敏已被证实的情况下作为一线治疗处方(声明 9);(3) 四联铋剂疗法(质子泵抑制剂、铋剂、甲硝唑)、铋剂、甲硝唑、四环素)作为一线疗法(声明 10);(4)铋剂四联疗法与质子泵抑制剂、左氧氟沙星和阿莫西林一起作为推荐的二线疗法(声明 11);(5)利福布汀阿莫西林三联疗法作为推荐的抢救疗法(声明 12)。结论:这些建议旨在为爱尔兰成人幽门螺杆菌感染的治疗提供当前最相关的最佳实践指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
期刊最新文献
A Systematic Review of Sleep Disturbance in Idiopathic Intracranial Hypertension. Advancing Patient Education in Idiopathic Intracranial Hypertension: The Promise of Large Language Models. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments. Approach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey. Association Between LACE+ Index Risk Category and 90-Day Mortality After Stroke.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1